10:46 AM EST, 11/06/2024 (MT Newswires) -- Plus Therapeutics ( PSTV ) said Wednesday it has signed a manufacturing services agreement with SpectronRx to produce Rhenium Obisbemeda, a radiotherapy for central nervous system cancers.

Financial details weren't disclosed.

Under the agreement SpectronRx will use its facilities to produce late-stage clinical and commercial supplies of Rhenium Obisbemeda, the company said.

The partnership aims to strengthen supply chain redundancy for Plus Therapeutics ( PSTV ), ensuring it can meet the demands of late-stage clinical trials and future commercial needs, the company said.

Shares of Plus Therapeutics ( PSTV ) were down 6.6% in recent Wednesday trading.

Price: 1.27, Change: -0.09, Percent Change: -6.62